69
Views
3
CrossRef citations to date
0
Altmetric
Case Report

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion

, , , , , , , & show all
Pages 1117-1120 | Published online: 01 Mar 2018

References

  • SasakiTRodigSJChirieacLRJannePAThe biology and treatment of EML4-ALK non-small cell lung cancerEur J Cancer201046101773178020418096
  • AnaiSTakeshitaMAndoNA case of lung adenocarcinoma resistant to crizotinib harboring a novel EML4-ALK variant, exon 6 of EML4 fused to exon 18 of ALKJ Thorac Oncol20161110e126e12827663401
  • WooCGSeoSKimSWDifferential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancerAnn Oncol201728479179728039177
  • ReguartNTeixidoCGimenez-CapitanAIdentification of ALK, ROS1, and RET fusions by a multiplexed mRNA-based assay in formalin-fixed, paraffin-embedded samples from advanced non-small-cell lung cancer patientsClin Chem201763375176028073897
  • YoshidaTOyaYTanakaKDifferential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancerJ Clin Oncol201634283383338927354483
  • RobesovaBBajerovaMHausnerovaJSkrickovaJTomiskovaMDvorakovaDIdentification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLCLung Cancer201587331832025601488